Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2008

VistaGen Expands Stem Cell Alliance with Canadian Institutes

  • VistaGen Therapeutics has expanded on its 10-year embryonic stem (ES) cell research alliance with Toronto's University Health Network and its stem cell research affiliate, the McEwen Centre for Regenerative Medicine.

    The new program builds on VistaGen's existing licenses to ES cell intellectual property owned by Gordon Keller, Ph.D., director of the McEwen Centre. It will also covers new ES cell-based research projects.  Taken together, VistaGen expects the studies to enhance drug testing and development equipment.

    VistaGen will continue to leverage Dr. Keller’s ES cell biology expertise and technologies. The firm and Dr. Keller will jointly conduct research into advanced techniques to differentiate ES cells into mature cardiac, liver, and pancreatic beta-islet cells.

    VistaGen anticipates that the partnership will advance its in vitro biological systems and bioinformatics databases for predictive toxicology applications.

    The new ES cell-based research projects will be used for R&D in customized ES cell-based heart, liver, and pancreatic beta-islet cell differentiation systems for drug discovering.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »